Publications, Studies, Posters and Abstracts

EventTitleDownloadCategoryYeardoc_categories_hfilterdoc_tags_hfilter
Molecular Med Tri-Con 2021Detection of EGFR Mutations in Quantity Insufficient Tissue Slides by High Sensitivity Assay Target Selector™ in Patients with Non-Small Cell Lung Cancer
Lung Cancer2021lung-cancer2021

ASCO 2020

Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF)
Technology Platform2020technology-platform2020

International Association for the Study of Lung Cancer (IASLC) 2020

Utility of Liquid Biopsy in Diagnosis and Treatment Response in EGFR Mutant NSCLC Patients with Leptomeningeal Involvement
Lung Cancer2020lung-cancer2020

Society for Neuro-Oncology 2020

Target Selector™ cerebrospinal fluid (CSF) circulating tumor cells and biomarker analysis: improving sensitivity and targeted treatment options in breast and NSCLC cancer patients with CNS involvement
Lung Cancer2020lung-cancer2020

San Antonio Breast Cancer Virtual Symposium 2020

HER2 Expression in Matched Metastatic Tumor and Circulating Tumor Cells (CTCs) In Breast Cancer: Implications for profiling and monitoring of HER2 status
Breast Cancer2020breast-cancer2020

University of Missouri at Kansas City, Kansas City 2019

Clinical utility of circulating tumor cell (CTC) analysis in patients with metastatic NSCLC receiving first-line chemotherapy
Lung Cancer2019lung-cancer2019

UC San Diego Health System 2019

Surrogate or Not: The Role for Cell Free Circulating DNA in Detecting EGFR Mutations Present in Tumor Tissue
Biomarkers2019biomarkers2019

PLOS ONE 2019

Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations
Lung Cancer2019lung-cancer2019

Clinics in Oncology – Breast Cancer 2019

Clinical Utility of Target Selector™ Circulating Tumor Cell (CTC) Testing in Tumor Marker Gene Amplification and Protein Expression in Metastatic Breast Cancer Management
Breast Cancer2019breast-cancer2019

Clinics in Oncology – General Oncology 2019

Demonstrated Clinical Utility of Target Selector™ ctDNA Testing: Liquid Biopsy EGFR Mutation Detection Enabled Targeted Therapy Selection for Three Advanced NSCLC
Lung Cancer2019lung-cancer2019

AMP 2019

Highly sensitive and specific detection of Cytokeratin Positive and Negative Circulating Tumor Cells
Technology Platform2019technology-platform2019

AMP 2019

Target Selector™ DNA EGFR kit for tissue demonstrates high sensitivity without the need for macro-dissection
Biomarkers2019biomarkers2019

AMP 2019

Mutant-p53 antibody stains cytokeratin negative CTCs enriched and detected with a “Pan-CTC” antibody cocktail
Biomarkers2019biomarkers2019

AMP 2019

Detection of Potential Epithelial Mesenchymal Transition Cells in Localized Prostate Cancer
Prostate Cancer2019prostate-cancer2019

AMP 2019

Monitoring breast cancer biomarkers from circulating tumor DNA using Target Selector™ NGS Breast Panel
Breast Cancer2019breast-cancer2019

AMP 2019

Validation of Target Selector™ Next Generation Sequencing Lung Panelfor the Detection of Circulating Tumor TNA Alterations
Lung Cancer2019lung-cancer2019

AACR 2019

Validation of a highly sensitive Target Selector™ ctDNA assay for ESR1 resistance mutations using an NGS enrichment strategy
Biomarkers2019biomarkers2019

World Conference in Lung Cancer 2019

The Dynamic Range of Mutant Allele Fraction Detected in Patients with NSCLC: Clinical Experience Data and Clinical Implications
Lung Cancer2019lung-cancer2019

San Antonio Breast Cancer Symposium 2019

Clinical Data in Over 1,500 Patients Across All Stages of Breast Cancer with Target Selector™ Circulating Tumor Cell Technology
Breast Cancer2019breast-cancer2019

Oncology & Hematology Review 2018

Detecting an ALK Rearrangement via Liquid Biopsy Enabled a Targeted Therapy-based Approach for Treating a Patient with Advanced Non-small Cell Lung Cancer
Lung Cancer2018lung-cancer2018

Journal of Thoracic Oncology 2018

ROS-1 Rearrangements in Circulating Tumor Cells
Biomarkers2018biomarkers2018

Biomarkers Summit 2018

Microfluidic Assay Detects dMMR in Circulating Tumor Cells (CTCs)
Biomarkers2018biomarkers2018

AACR-IASLC 2018

Validation of the QuantStudio5 Instrument for Use in Biocept’s TargetSelector™ ctDNA Lung Cancer Assays
Technology Platform2018technology-platform2018

AACR 2018

TargetSelector™ CTC technology demonstrates clinical utility in monitoring treatment response in germ cell tumors (testicular cancer)
Technology Platform2018technology-platform2018

AACR 2018

Validation of Highly Sensitive Target Selector™ ctDNA Assays for EGFR, BRAF, and KRAS Mutations
Biomarkers2018biomarkers2018

World Conference in Lung Cancer 2018

Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM
Lung Cancer2018lung-cancer2018

Journal of Thoracic Oncology 2017

Clinical Utility of Plasma EGFR T790M Mutation Detection in Advanced Non-Small Cell Lung Cancer Patients According to RECIST Criteria
Lung Cancer2017lung-cancer2017

ASCO 2017

Biocept’s Sample Collection for Tumor Cell Analysis Demonstrates Superior Performance
Technology Platform2017technology-platform2017

ASCO 2017

Clinical Experience in ctDNA Profiling of NSCLC 2000 Cases Using TargetSelector™ Demonstrates High Sensitivity
Lung Cancer2017lung-cancer2017

AACR 2017

A concordance study of the ArcherDx Reveal ctDNA 28 NGS panel and Biocept’s Target-Selector™ mutation assay using ctDNA collected in Biocept’s CEE-sure blood collection tube
Technology Platform2017technology-platform2017

ESMO 2016

Clinical evaluation of the utility of a liquid biopsy (Circulating tumoral cells and ctDNA) to determine the mutational profile (EGFR, KRAS, ALK, ROS1 and BRAF) in advanced NSCLC patients.
Lung Cancer2016lung-cancer2016

ASCO 2016

The performance of a comprehensive CTC anti-body capture cocktail in the detection and phenotypic analysis of CTCs
Technology Platform2016technology-platform2016

San Antonio Breast Cancer Symposium 2016

Circulating Tumor Cell (CTC) Biomarker Evaluation from Patients with Metastatic Breast Cancer (MBC) Utilizing the Target Selector™ Platform
Breast Cancer2016breast-cancer2016

Clinical Translational Oncology 2015

Correlation of hormone receptor status between circulating tumor cells, primary tumor and metastasis in breast cancer patients
Breast Cancer2015breast-cancer2015

ASCO 2015

Clinical validation and utility of a liquid biopsy for non-small cell lung carcinoma utilizing CTCs and ctDNA to analyze ALK, ROS and EGFR status
Lung Cancer2015lung-cancer2015

AACR 2015

High Sensitivity Detection of Rare EGFR Mutations with ctDNA using Target-Selector™ Assays
Biomarkers2015biomarkers2015

Molecular Assay Development 2015

Validation of PD-L1 Expression on Circulating Tumor Cells in Lung Cancer
Lung Cancer2015lung-cancer2015

San Antonio Breast Cancer Symposium 2014

Prospective characterization of HER2-positive circulating tumor cells in patients with HER2- negative metastatic breast cancer
Breast Cancer2014breast-cancer2014

Cancer Cell 2014

Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Ovarian Cancer2014ovarian-cancer2014

Cancer Medicine 2013

Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer
Biomarkers2013biomarkers2013

ASCO 2012

Estrogen receptor and progesterone receptor immunocytochemistry staining in circulating tumor cells as compared to primary tumor or metastatic biopsy
Biomarkers2012biomarkers2012

ASCO 2012

Detection of discordant HER2 status by FISH in circulating tumor cells and disseminated tumor cells in early stage breast cancer using a microfluidicbased cell enrichment and extraction platform (OncoCEE™)
Biomarkers2012biomarkers2012

ASCO 2012

Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing
Breast Cancer2012breast-cancer2012

AACR 2012

The CEE-Selector™ Assay: A tool for the identification of rare allele variants
Technology Platform2012technology-platform2012

San Antonio Breast Cancer Symposium 2011

Estrogen receptor and progesterone receptor immunocytochemistry staining in circulating tumor cells as compared to primary tumor or metastatic biopsy
Biomarkers2011biomarkers2011

San Antonio Breast Cancer Symposium 2011

Detection of HER2 gene amplification in circulating tumor cells and disseminated tumor cells by fluorescence in situ hybridization using OncoCEE™
Biomarkers2011biomarkers2011

Molecular Med Tri-Con 2011

Detection of EpCAM-negative and Cytokeratin-negative Circulating Tumor Cells in Peripheral Blood
Technology Platform2011technology-platform2011

Cancer Genetics 2011

FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform
Biomarkers2011biomarkers2011

Cancer Discovery 2011

A Novel Platform for Detection of CK+ and CK- CTCs
Technology Platform2011technology-platform2011

Biomicrofluidics 2011

Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device
Technology Platform2011technology-platform2011

Biomicrofluidics 2011

Efficient Capture of Suspended Tumor Cells with a Novel Immunocytochemical Microfluidic Device
Technology Platform2011technology-platform2011

ASCO 2011

Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISH
Technology Platform2011technology-platform2011

ASCO 2011

Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology [CEE™])
Biomarkers2011biomarkers2011

AACR 2011

Fluorescence labeling of cytokeratin-negative circulating tumor cells in peripheral blood: A new paradigm for the study of cancer progression
Technology Platform2011technology-platform2011

AACR 2011

Redefining CTCs: Detection of cytokeratin-negative circulating tumor cells (CTCs)
Technology Platform2011technology-platform2011

The Journal of Urology 2010

Recovery of Circulating Tumor Cells in Urothelial Carcinoma Cell Lines Utilizing a Novel Antibody Based Microfluidic Cell Capture Technique
Technology Platform2010technology-platform2010

San Antonio Breast Cancer Symposium 2010

Detection of circulating tumor cells and HER2 gene amplification status in breast cancer using a novel microfluidic platform (Cell Enrichment and Extraction Technology, CEE™)
Biomarkers2010biomarkers2010
CEE™ Cell Enrichment and Extraction Technology Enabling Early, Non-invasive Isolationof Rare Cells for Diagnostics
Technology Platform2007technology-platform2007
Mouse Models for MEMS (Micro-Electro-Mechanical System) Based Biomarker Discovery: A Novel CTC Mouse-Trap
Technology Platformtechnology-platform
Comparison of fluorescence in situ hybridization of estrogen receptor genetic locus with protein expression in invasive breast carcinoma
Technology Platformtechnology-platform